-+ 0.00%
-+ 0.00%
-+ 0.00%
According to the Xingqi Pharmaceutical announcement, the SQ-24071 eye drops developed by the company completed the enrollment of the first test subjects and officially entered the Phase I clinical trial. The drug is classified as a chemical drug of class 2.2 and 2.4, and is intended to slow the progression of myopia in children and adolescents. The Phase I trial is a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability and pharmacokinetic characteristics of the drug among myopic children and adolescents. As of the date of disclosure of the announcement, this ophthalmic preparation product has not yet been marketed at home or abroad. This enrollment will not have a significant impact on the company's recent performance, and there is uncertainty about the progress and results of drug clinical trials.
Share
Listen to the news
According to the Xingqi Pharmaceutical announcement, the SQ-24071 eye drops developed by the company completed the enrollment of the first test subjects and officially entered the Phase I clinical trial. The drug is classified as a chemical drug of class 2.2 and 2.4, and is intended to slow the progression of myopia in children and adolescents. The Phase I trial is a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability and pharmacokinetic characteristics of the drug among myopic children and adolescents. As of the date of disclosure of the announcement, this ophthalmic preparation product has not yet been marketed at home or abroad. This enrollment will not have a significant impact on the company's recent performance, and there is uncertainty about the progress and results of drug clinical trials.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending